Bloomberg: Takeda may face 10,000 Actos claims

When the FDA found that the Takeda Pharmaceutical drug Actos might actually increase the risk of bladder cancer, the lawsuits were inevitable. Now, lawyers tell Bloomberg that the Japanese drugmaker may end up fighting as many as 10,000 claims in U.S. courts. To prepare for the onslaught, some U.S. judges are considering where to consolidate the legal battles.

As Bloomberg reports, plaintiffs' attorney Paul Pennock was due to appear in Savannah, GA, court today to argue for consolidation in Louisiana or Ohio. Pennock represents 1,200 Actos patients and expects to add many more. "We are getting calls every day about Actos," he told the news service.

Takeda spokesman Mitsuo Oguri told the news service that the company has already revised U.S. and Japanese patient-information materials to include risk data on bladder cancer. It's in the process of updating patient leaflets in Europe, the spokesman said, adding, "Takeda remains confident on the efficacy of pioglitazone for treating type 2 diabetes, while it continues to monitor the safety profile of the medicine."

- see the Bloomberg story

Special Report: Takeda Pharmaceutical - 10 Largest U.S. Patent Losses

Related Articles:
FDA highlights cancer risk with Takeda's Actos
French officials force Takeda to pull Actos off market
EMA wants Actos warning, weighs in on Chantix

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.